Form 4: Director John Roush Boosts LMAT Holdings

Lemaitre Vascular Director John Roush reported the acquisition of 533 restricted stock units and 3,431 stock options, increasing his beneficial ownership.

Summary

• Director John A. Roush of Lemaitre Vascular Inc. (LMAT) reported changes in his beneficial ownership.
• Acquired 533 shares of Common Stock as a restricted stock unit (RSU) award on December 10, 2025, with a transaction price of $0.
• The RSU award vests 33 1/3% on December 1, 2026, with the balance vesting in equal annual installments over the subsequent two years.
• Acquired 3,431 stock options on December 10, 2025, with an exercise price of $83.66 and a transaction price of $0.
• These stock options expire on December 10, 2030, and vest over a three-year period, with 33 1/3% vesting on the first anniversary of the grant date (December 10, 2025) and the balance in equal annual installments over the remaining two years.
• Following these transactions, Roush directly owns 3,455 shares of Common Stock and 3,431 stock options, and indirectly owns 181 shares through his spouse.

Sentiment

Score: 7

Explanation: The filing indicates a positive alignment of director interests with shareholders through equity compensation, which is generally viewed favorably. It's a routine compensation event, not a major strategic announcement, hence a moderate positive score.

Positives

• Director John Roush received a significant equity award, aligning his interests further with shareholders.
• The acquisition of 533 restricted stock units and 3,431 stock options indicates continued commitment from a key director.

Future Outlook

The vesting schedules for the restricted stock units and stock options extend over three years, indicating a long-term incentive structure for the director.

Industry Context

This Form 4 filing reflects standard equity compensation practices for directors in the medical device industry, aiming to align executive incentives with long-term shareholder value creation. Such grants are common for retaining and motivating key personnel in competitive sectors like healthcare technology.

Comparison to Industry Standards

• Equity grants to directors, particularly in the form of restricted stock units and stock options with multi-year vesting schedules, are a common practice across the medical device and broader technology sectors.
• Companies like Medtronic (MDT) and Boston Scientific (BSX) frequently utilize similar long-term incentive plans to compensate and retain their board members and executives, aligning their interests with company performance over several years.
• The specific size of the grant would typically be benchmarked against peer companies of similar market capitalization and revenue within the industry.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with long-term shareholder value through equity compensation.

Next Steps

• Vesting of 33 1/3% of restricted stock units on December 1, 2026, with subsequent annual installments.
• Vesting of 33 1/3% of stock options on December 10, 2026, with subsequent annual installments.
• Potential exercise of stock options before their expiration on December 10, 2030.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a director, which is a standard practice to align management incentives with shareholder interests. It does not provide new fundamental information about the company's operational performance, financial health, or strategic direction that would warrant a change in an existing investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Lemaitre Vascular, LMAT, Form 4, Insider Trading, Director Stock Acquisition, Restricted Stock Units, Stock Options, Equity Compensation, John Roush